Testing a pharmaceutical drug is a multi-stage process that typically takes 10 to 15 years and costs between $1 billion and $2 billion, including the cost of all the drugs that fail along the way. The process moves from laboratory experiments to animal studies, then through increasingly large human trials, and finally to regulatory review and ongoing safety monitoring after the drug reaches the market.
Pre-Clinical Testing: Lab and Animal Studies
Before a drug ever enters a human body, it goes through extensive laboratory testing. The first round happens in cell cultures, where researchers expose human or animal cells to the compound to observe its biological activity. These in vitro experiments measure things like how strongly the drug binds to its target receptor, what it does to cell behavior and growth, and whether it damages cells it’s not supposed to affect. For drugs based on antibodies, researchers also test whether the compound accidentally reacts with human tissues beyond its intended target, using samples from a range of tissue types.
If the drug looks promising in cell studies, it moves to animal testing. The goal here is to identify toxic effects in a living system before risking human health. Researchers must choose a “relevant species,” meaning an animal whose biology responds to the drug in a way that’s comparable to a human response. Sometimes no natural animal model exists. In those cases, scientists may use genetically engineered animals that express human receptors, or they may test a closely related version of the drug that does work in the available animal species. When even those options aren’t feasible, a limited toxicity study in a single species lasting less than 14 days can still provide useful safety signals, particularly for effects on the heart and lungs.
Animal studies also use disease models to see if the drug actually works against the condition it’s meant to treat. These include animals that naturally develop a similar disease, animals in which a disease has been chemically or surgically induced, and animals with specific genes knocked out or added to mimic human conditions.
Phase I: First Tests in Humans
Phase I trials are the first time a drug enters a human body. These studies enroll a small group, typically 20 to 80 people, and the primary goal is safety rather than effectiveness. Researchers start with very low doses and gradually increase them, watching closely for side effects. Participants are usually healthy volunteers, though for certain drugs (particularly cancer treatments) they may be patients with the disease being targeted.
These trials also measure how the body processes the drug: how quickly it’s absorbed, how it’s broken down, how long it stays active, and how it’s eliminated. This information helps researchers determine what doses to use in the next phase of testing.
Phase II and III: Proving the Drug Works
Phase II trials expand the study to a larger group of patients who actually have the condition the drug is designed to treat. Researchers test different dosing strategies and begin collecting data on whether the drug produces a meaningful therapeutic effect. These studies also continue to track side effects.
Phase III trials are the large-scale studies that determine whether a drug earns regulatory approval. They can involve hundreds or thousands of participants across multiple hospitals or clinics. The gold standard design is the randomized, double-blind, placebo-controlled trial. Participants are randomly assigned to receive either the experimental drug or a comparison (often a placebo or the current standard treatment), and neither the patient nor the medical staff knows which one any individual received. This blinding guards against the placebo effect, where patients improve simply because they believe they’re being treated, and it prevents doctors from unconsciously scoring outcomes more favorably for people they know are getting the real drug.
Some trials go further with “triple-blinding,” where even the statisticians analyzing the data don’t know which group received which treatment until the analysis is complete. The level of blinding depends on the study, but the core principle is the same: remove human bias from the measurement of results.
Quality Control During Manufacturing
Testing doesn’t stop at clinical trials. Every batch of a drug that comes off a production line must be tested to confirm it contains the right amount of active ingredient and hasn’t degraded. The workhorse method for this is high-performance liquid chromatography, or HPLC, which separates a drug sample into its individual chemical components so each one can be measured precisely. HPLC is preferred because it’s both specific (it can distinguish the drug from closely related molecules) and efficient.
Other testing methods fill different roles. Titration uses chemical reactions to measure drug concentration. Microbial assays are sometimes used for antibiotics. UV-visible spectrophotometry can measure drug strength in simple solutions, though it works only when there’s a single ingredient to measure.
Stability testing is equally important. A stability-indicating assay tracks whether a drug is breaking down over time by separating degradation products from the intact drug and measuring how the drug’s concentration changes. Manufacturers validate these methods against a set of analytical benchmarks: accuracy, precision, specificity, detection limits, and more. A photodiode array detector can scan across ultraviolet wavelengths to calculate “peak purity,” confirming that what appears to be the drug in the results is truly just the drug and not a mixture of the drug plus a breakdown product hiding underneath.
FDA Review and Approval
Once Phase III trials are complete, the drug manufacturer compiles all the data, from pre-clinical studies through clinical trials and manufacturing quality data, into a formal application submitted to the FDA. If the application is complete, the FDA review team has 6 to 10 months to make a decision on whether to approve the drug.
The FDA also offers several programs that can speed up the process for drugs that address critical needs. Fast Track designation is available for drugs that treat serious conditions where no adequate treatment exists, and it allows for more frequent communication with the FDA during development. Breakthrough Therapy designation goes a step further, reserved for drugs that show substantial improvement over existing options. Accelerated Approval allows drugs for serious conditions to be approved based on a surrogate endpoint, such as a lab measurement that predicts clinical benefit, rather than waiting for long-term outcome data. Priority Review shortens the FDA’s goal for its decision timeline to 6 months.
Phase IV: Monitoring After Approval
Approval is not the end of testing. Phase IV trials evaluate drug safety in real-world conditions, outside the controlled environment of earlier clinical trials. Since 2007, the FDA has had the authority to require manufacturers to conduct post-market studies when safety concerns arise.
These studies differ from pre-approval trials in important ways. They often use simpler designs: single-arm studies, non-randomized comparisons, or open-label trials where everyone knows what they’re receiving. About 76% of Phase IV safety trials enroll fewer than 300 participants, and 96.5% enroll fewer than 3,000. The sample size matters because rare side effects require large numbers to detect. To have a 95% chance of observing at least one case of a side effect that occurs in 1% of patients, you need more than 300 participants. For a side effect occurring in just 0.1% of patients, you need more than 3,000.
All of these trials are registered on ClinicalTrials.gov, a public database maintained by the National Library of Medicine. Since 2007, trial sponsors have been legally required to register their studies and report basic results there, making post-market safety data publicly accessible.